Beam Therapeutics Inc.
BEAM
$28.79
$2.057.67%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.70M | 8.47M | 7.47M | 30.07M | 14.27M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.70M | 8.47M | 7.47M | 30.07M | 14.27M |
| Cost of Revenue | 109.77M | 101.76M | 98.82M | 101.44M | 94.26M |
| Gross Profit | -100.07M | -93.29M | -91.35M | -71.38M | -79.99M |
| SG&A Expenses | 26.74M | 26.86M | 27.94M | 28.66M | 26.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 136.51M | 128.62M | 126.76M | 130.10M | 120.77M |
| Operating Income | -126.81M | -120.15M | -119.29M | -100.04M | -106.50M |
| Income Before Tax | -112.73M | -102.29M | -109.27M | -90.35M | -96.67M |
| Income Tax Expenses | -- | -- | -- | 0.00 | -- |
| Earnings from Continuing Operations | -112.73M | -102.29M | -109.27M | -90.35M | -96.67M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -112.73M | -102.29M | -109.27M | -90.35M | -96.67M |
| EBIT | -126.81M | -120.15M | -119.29M | -100.04M | -106.50M |
| EBITDA | -121.25M | -114.61M | -113.76M | -94.59M | -101.03M |
| EPS Basic | -1.10 | -1.00 | -1.24 | -1.09 | -1.17 |
| Normalized Basic EPS | -0.72 | -0.65 | -0.76 | -0.67 | -0.72 |
| EPS Diluted | -1.10 | -1.00 | -1.24 | -1.09 | -1.17 |
| Normalized Diluted EPS | -0.72 | -0.65 | -0.76 | -0.67 | -0.72 |
| Average Basic Shares Outstanding | 102.57M | 102.00M | 87.98M | 82.82M | 82.41M |
| Average Diluted Shares Outstanding | 102.57M | 102.00M | 87.98M | 82.82M | 82.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |